Omega Therapeutics stock enters liquidation after August 8, 2025 plan date

Published on 09/25/2026 at 15:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Omega Therapeutics stock is tied to a liquidation plan effective August 8, 2025. The Chapter 11 case lists USD 100 million to USD 500 million in assets and liabilities.

OMGA, US68218K1025, Illustration mit AI erstellt.

Omega Therapeutics stock is now associated with a post-effective-date liquidation under a plan that became effective on August 8, 2025. The case remains active for claims administration, with a November 2, 2026 deadline providing the clearest dated checkpoint for the company.

Liquidation plan took effect

According to ElevenFlo, the plan was confirmed on July 31, 2025, and became effective eight days later on August 8, 2025. That sequence marks the shift from court confirmation to post-effective-date administration.

The bankruptcy petition was filed on February 10, 2025, under case number 25-10211 in the United States Bankruptcy Court for the District of Delaware, according to ElevenFlo. The petition listed assets of USD 100 million to USD 500 million and liabilities in the same USD 100 million to USD 500 million range.

Claims process sets next date

The current process centers on reconciling claims and making distributions under the confirmed plan. A post-confirmation report filed on July 16, 2026, and a final notice of unclaimed distributions filed on July 23, 2026, are listed among the recent case documents by ElevenFlo.

The next material milestone is the November 2, 2026 claims-objection deadline established by an extension order, the case summary states. For holders and claimants, the dated court process matters more than conventional earnings milestones because the plan is already effective.

Case status remains the key figure

Omega Therapeutics operates in healthcare, while the bankruptcy case is listed in Delaware and names Brendan Linehan Shannon as judge, according to ElevenFlo. The contrast between the February 10, 2025 petition date and the November 2, 2026 claims deadline shows that the proceeding has moved from filing to post-confirmation administration.

Omega Therapeutics stock and the case

Omega Therapeutics stock is therefore best understood through the legal timetable: plan confirmation on July 31, 2025, effectiveness on August 8, 2025, and claims objections due on November 2, 2026. Those dates define the current company-specific framework.